Abstract Number: 2593 • 2013 ACR/ARHP Annual Meeting
The Prognosis Of Scleroderma Renal Crisis In RNA-Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients
Background/Purpose: Scleroderma renal crisis (SRC) usually presenting with accelerated hypertension and acute kidney injury (AKI) is one of the most severe complications of Systemic Sclerosis…Abstract Number: 1936 • 2012 ACR/ARHP Annual Meeting
The Human Leukocyte Antigen DRB1*13:02-DQB1*06:04-DPB1*04:01 Haplotype Is Closely Associated with Dermatomyositis Patients with Anti-CADM-140 (Melanoma Differentiation-Associated Protein 5: MDA5) Antibody
Background/Purpose: Recent studies have revealed that anti-CADM-140 (MDA5/IFIH1)-antibody positive dermatomyositis (DM) patients frequently develop acute or subacute progressive interstitial pneumonia (A/SIP) with poor prognosis. However,…Abstract Number: 1748 • 2012 ACR/ARHP Annual Meeting
Antibody Secreting Cells Arising After Vaccination of Lupus Patients May Produce High Affinity Autoantibodies
Background/Purpose: Vaccinating SLE patients with influenza and pneumococcal vaccines is generally considered safe and effective. However, conflicting reports regarding the impact of vaccination on autoantibody…Abstract Number: 1491 • 2012 ACR/ARHP Annual Meeting
Systemic Sclerosis – Effects of Agonistic Autoantibodies Directed Against the Angiotensin Receptor Type 1 and the Endothelin Receptor Type A On Effector Cells
Background/Purpose: Autoimmunity, vasculopathy and fibrosis are features of systemic sclerosis (SSc). The functional link between these three pathophysiological components is still missing. Research suggests an…Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…Abstract Number: 1178 • 2012 ACR/ARHP Annual Meeting
IL-6 and IL-21 in Rheumatoid Arthritis
Background/Purpose: Interleukin-6 (IL-6) levels are known to be increased in patients with rheumatoid arthritis (RA). Tocilizumab, a monoclonal antibody to the IL-6 receptor (IL-6R), reduces…Abstract Number: 948 • 2012 ACR/ARHP Annual Meeting
Antibody-Based Prediction Rules for Connective Tissue Disease: Analysis of 12,555 Patients with Antinuclear Antibody Testing
Background/Purpose: Antinuclear antibody (ANA) is widely used as a screening test for connective tissue diseases (CTDs). The sensitivity of this test is high in 3…Abstract Number: 835 • 2012 ACR/ARHP Annual Meeting
Low Doses of Ocaratuzumab, a Fc- and Fab-Engineered Anti-CD20 Antibody, Result in Rapid and Sustained Depletion of Circulating B-Cells in Rheumatoid Arthritis Patients
Background/Purpose: B-cell depletion provides therapeutic benefits for patients with rheumatoid arthritis (RA). Ocaratuzumab, previously known as AME-133v, is a Fc- and Fab-engineered, humanized, anti-CD20…Abstract Number: 836 • 2012 ACR/ARHP Annual Meeting
Clinical Responses and Patient Reported Outcomes to NNC0109-0012 (anti-IL-20 mAb) in Rheumatoid Arthritis (RA) Patients Following 12-Weeks Dosing and 13 Weeks Follow up: Results From a Phase 2a Trial
Background/Purpose: NNC0109-0012 (anti-IL-20 mAb) is a novel human monoclonal IgG4 antibody which binds to and neutralizes the activity of IL-20. Data from a phase 1…Abstract Number: 683 • 2012 ACR/ARHP Annual Meeting
Prevalence of Inhibitory or Non-Inhibitory Autoantibodies to Angiotensin Converting Enzyme 2 (ACE2) in Patients with Systemic Lupus Erythematosus
Background/Purpose: We previously reported that inhibitory autoantibodies to angiotensin converting enzyme 2 (ACE2) predisposed individuals to connective tissue diseases (i.e., scleroderma or systemic lupus erythematosus…Abstract Number: 665 • 2012 ACR/ARHP Annual Meeting
Cytokines and Their Relation to Autoantibodies Before Disease Onset in Systemic Lupus Erythematosus
Background/Purpose: Cytokines and autoantibodies are involved in the pathogenesis of systemic lupus erythematosus (SLE). The presence of autoantibodies preceding disease onset by years has been…Abstract Number: 485 • 2012 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients
Background/Purpose: To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA). Methods: Sera…Abstract Number: 349 • 2012 ACR/ARHP Annual Meeting
Preliminary Results From a Controlled Study Assessing the Humoral Immune Response to Vaccines in Rheumatoid Arthritis Patients Treated with Tocilizumab
Background/Purpose: Tocilizumab (TCZ) is an IL-6–receptor inhibitor for treatment of rheumatoid arthritis (RA) patients (pts). Because TCZ may impact how IL-6 modulates T-cell activation and…Abstract Number: 2659 • 2012 ACR/ARHP Annual Meeting
An Expanded Repertoire of Anti-Citrullinated Peptide Antibodies Is Associated with Interstitial Lung Disease in Rheumatoid Arthritis
Background/Purpose: Interstitial lung disease (ILD) is an outcome with high morbidity and mortality in rheumatoid arthritis (RA). Citrullinated proteins are observed in these lung tissues;…Abstract Number: 286 • 2012 ACR/ARHP Annual Meeting
The Association of N-Methyl-D-Aspartate Receptor Antibodies and Neurocognitive Dysfunction in Pediatric Lupus Patients and in the Offspring of Adult Patients with Lupus
Background/Purpose: Approximately 1/5 of all systemic lupus erythematosus (SLE) starts in childhood and central nervous system (CNS) dysfunction is more common in childhood-onset SLE. CNS…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- Next Page »